These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
484 related articles for article (PubMed ID: 12930147)
41. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. Zhao GM; Qian X; Schiller PW; Szeto HH J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366 [TBL] [Abstract][Full Text] [Related]
42. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities. Lattanzi R; Spetea M; Schüllner F; Rief SB; Krassnig R; Negri L; Schmidhammer H J Med Chem; 2005 May; 48(9):3372-8. PubMed ID: 15857143 [TBL] [Abstract][Full Text] [Related]
43. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Lester PA; Traynor JR Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205 [TBL] [Abstract][Full Text] [Related]
44. Synthesis of 6,14-epoxymorphinan derivatives and their pharmacologies. Nemoto T; Yamamoto N; Watanabe A; Fujii H; Hasebe K; Nakajima M; Mochizuki H; Nagase H Bioorg Med Chem; 2011 Feb; 19(3):1205-21. PubMed ID: 21256034 [TBL] [Abstract][Full Text] [Related]
45. Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies. Colotta V; Catarzi D; Varano F; Lenzi O; Filacchioni G; Costagli C; Galli A; Ghelardini C; Galeotti N; Gratteri P; Sgrignani J; Deflorian F; Moro S J Med Chem; 2006 Oct; 49(20):6015-26. PubMed ID: 17004715 [TBL] [Abstract][Full Text] [Related]
46. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor. Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963 [TBL] [Abstract][Full Text] [Related]
47. N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. Volpini R; Dal Ben D; Lambertucci C; Taffi S; Vittori S; Klotz KN; Cristalli G J Med Chem; 2007 Mar; 50(6):1222-30. PubMed ID: 17309246 [TBL] [Abstract][Full Text] [Related]
49. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951 [TBL] [Abstract][Full Text] [Related]
50. Glutamate receptor ligands: synthesis, stereochemistry, and enantiopharmacology of methylated 2-aminoadipic acid analogs. Guldbrandt M; Johansen TN; Frydenvang K; Bräuner-Osborne H; Stensbøl TB; Nielsen B; Karla R; Santi F; Krogsgaard-Larsen P; Madsen U Chirality; 2002 May; 14(4):351-63. PubMed ID: 11968078 [TBL] [Abstract][Full Text] [Related]
51. Synthesis, structure and affinity of novel 3-alkoxy-1,2-dihydro-3H-1,4-benzodiazepin-2-ones for CNS central and peripheral benzodiazepine receptors. Andronati S; Semenishyna E; Pavlovsky V; Simonov Y; Makan S; Boyko I; Burenkova N; Gdaniec M; Cardinael P; Bouillon JP; Mazepa A Eur J Med Chem; 2010 Apr; 45(4):1346-51. PubMed ID: 20061068 [TBL] [Abstract][Full Text] [Related]
52. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997 [TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and preliminary pharmacological evaluation of new quinoline derivatives as nicotinic ligands. Guandalini L; Norcini M; Varani K; Pistolozzi M; Gotti C; Bazzicalupi C; Martini E; Dei S; Manetti D; Scapecchi S; Teodori E; Bertucci C; Ghelardini C; Romanelli MN J Med Chem; 2007 Oct; 50(20):4993-5002. PubMed ID: 17850058 [TBL] [Abstract][Full Text] [Related]
54. N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice. Franchetti P; Cappellacci L; Vita P; Petrelli R; Lavecchia A; Kachler S; Klotz KN; Marabese I; Luongo L; Maione S; Grifantini M J Med Chem; 2009 Apr; 52(8):2393-406. PubMed ID: 19317449 [TBL] [Abstract][Full Text] [Related]
55. Structure-activity relationships of dynorphin a analogues modified in the address sequence. Schlechtingen G; DeHaven RN; Daubert JD; Cassel JA; Chung NN; Schiller PW; Taulane JP; Goodman M J Med Chem; 2003 May; 46(11):2104-9. PubMed ID: 12747782 [TBL] [Abstract][Full Text] [Related]
56. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan. Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100 [TBL] [Abstract][Full Text] [Related]